Literature DB >> 25836929

Diagnosis and staging of bladder cancer.

Maxine Sun1, Quoc-Dien Trinh2.   

Abstract

Bladder cancer (BCa) is a heterogeneous disease with a variable natural history. Most patients (70%) present with superficial tumors (stages Ta, T1, or carcinoma in situ). However, 3 out of 10 patients present with muscle-invasive disease (T2-4) with a high risk of death from distant metastases. Moreover, roughly between 50% and 70% of superficial tumors do recur, and approximately 10% to 20% of them progress to muscle-invasive disease. However, BCa has a relatively low ratio of mortality versus incidence of new cases. In consequence, there is the danger of overdiagnosis and overtreatment.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarkers; Bladder cancer; Cystoscopy; Diagnosis; Imaging; Screening; Staging; Urothelial carcinoma of the bladder

Mesh:

Substances:

Year:  2014        PMID: 25836929     DOI: 10.1016/j.hoc.2014.10.013

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  25 in total

Review 1.  Current Status of Robot-Assisted Radical Cystectomy and Intracorporeal Urinary Diversion.

Authors:  Raj Kurpad; Michael Woods; Raj Pruthi
Journal:  Curr Urol Rep       Date:  2016-06       Impact factor: 3.092

2.  Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.

Authors:  Sasinya N Scott; Irina Ostrovnaya; Caroline M Lin; Nancy Bouvier; Bernard H Bochner; Gopakumar Iyer; David Solit; Michael F Berger; Oscar Lin
Journal:  Cancer Cytopathol       Date:  2017-03-24       Impact factor: 5.284

Review 3.  Current Concepts in the Management of Muscle Invasive Bladder Cancer.

Authors:  Suprita R Krishna; Badrinath R Konety
Journal:  Indian J Surg Oncol       Date:  2016-12-15

Review 4.  Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives.

Authors:  Sen Liu; Xu Chen; Tianxin Lin
Journal:  J Adv Res       Date:  2021-11-24       Impact factor: 12.822

5.  Comprehensive analysis of autophagy related long non-coding RNAs in prognosis, immunity, and treatment of muscular invasive bladder cancer.

Authors:  Hao Wu; Zili Hu; Wei Tan; Ye Yuan; Hao Huang; Junhao Ma; Yadong Li; Yuanqing Gou
Journal:  Sci Rep       Date:  2022-07-04       Impact factor: 4.996

6.  Identification of hub genes associated with bladder cancer using bioinformatic analyses.

Authors:  Wei Zheng; Yubo Zhao; Tengshuang Wang; Xiaoling Zhao; Zhangsen Tan
Journal:  Transl Cancer Res       Date:  2022-05       Impact factor: 0.496

Review 7.  Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer.

Authors:  Lillian Y Lai; Sean M Tafuri; Emily C Ginier; Lindsey A Herrel; Philipp Dahm; Philipp Maisch; Giulia Ippolito Lane
Journal:  Cochrane Database Syst Rev       Date:  2022-04-08

Review 8.  The Role of Molecular Imaging in a Muscle-Invasive Bladder Cancer Patient: A Narrative Review in the Era of Multimodality Treatment.

Authors:  Vincenzo Cuccurullo; Giuseppe Danilo Di Stasio; Francesco Manti; Pierpaolo Arcuri; Rocco Damiano; Giuseppe Lucio Cascini
Journal:  Diagnostics (Basel)       Date:  2021-05-11

9.  High VEGF-D and Low MMP-2 Serum Levels Predict Nodal-Positive Disease in Invasive Bladder Cancer.

Authors:  Tobias Benoit; Etienne X Keller; Pirmin Wolfsgruber; Thomas Hermanns; Michele Günthart; Irina Banzola; Tullio Sulser; Maurizio Provenzano; Cédric Poyet
Journal:  Med Sci Monit       Date:  2015-08-04

10.  Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer.

Authors:  Ying-Li Lin; Yan-Ling Wang; Xing-Li Fu; Wen-Ping Li; Yu-Hao Wang; Jian-Guo Ma
Journal:  Oncotarget       Date:  2016-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.